The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

Zacks highlighted Goldman Sachs, RTX, Abbott, NL Industries and Precipio in a research roundup, with generally balanced assessments rather than rating changes or new financial results. Goldman Sachs has outperformed its industry by 33.7% over the past year, supported by repeated earnings beats and investment-banking recovery, while RTX's $289 billion Q2 2026 backlog supports aerospace and defense growth despite supply-chain and tariff risks. Abbott maintained sales guidance and raised EPS guidance, but Zacks retained a Neutral view given diagnostics volatility, China pricing pressure and acquisition-related risks.

Analysis

This is low-information sell-side distribution rather than a fundamental catalyst; it should not alter positions in GS, RTX, or ABT absent revised estimates, management disclosures, or order data. The most actionable implication is dispersion: GS’s fee-income and capital-return narrative is most sensitive to a sustained reopening in M&A and underwriting, while RTX’s valuation will hinge on whether supply constraints convert backlog into revenue rather than merely preserve a large headline backlog. ABT’s raised earnings outlook is less meaningful if it is driven by mix, buybacks, or temporary cost actions rather than accelerating device and Libre utilization.

Over the next 1-3 months, monitor GS advisory/underwriting fee estimates and compensation accruals; positive deal announcements without upward 2027 revenue revisions would make the stock vulnerable after its relative outperformance. For RTX, commercial engine shop-visit throughput and OEM delivery schedules are the key gating variables: delayed deliveries can shift cash conversion despite robust demand, favoring aftermarket-exposed peers such as GE Aerospace (GE) if RTX execution slips. For ABT, China lab-pricing developments and post-acquisition financing terms are more material than incremental commentary on portfolio diversification.

The contrarian point is that the cited performance gaps already embed much of the broad recovery narrative for GS and RTX. A soft landing with lower rates can support capital markets activity, but it also compresses net interest income and can expose elevated expense bases across brokers; GS needs operating leverage, not simply better market sentiment. The microcaps PRPO and NL lack sufficient liquidity and independently verified near-term earnings catalysts for institutional deployment; any price response to research coverage is more likely technical than durable.

Key Decisions for Investors

• No event-driven trade on this release; require consensus-estimate changes or company-level disclosures before adding risk.
• Maintain a 1-3 month relative-value watch: long GE / short RTX only if RTX confirms engine-delivery or free-cash-flow conversion slippage while GE aftermarket revenue guidance remains intact. Exit if RTX reaffirms delivery cadence and cash conversion; target a 5-8% relative move with a 3% spread stop.
• For GS, avoid chasing strength ahead of the next earnings cycle. Add only if advisory and underwriting revenue consensus rises meaningfully while compensation-to-revenue expectations remain stable; a guidance-led operating-leverage upgrade is the catalyst, while flat fee estimates or higher provisions falsify the thesis.
• Keep ABT market-weight pending verifiable resolution of China pricing and acquisition financing/dilution terms. A long ABT / short EXAS hedge becomes actionable only if cancer-diagnostics cross-selling targets are quantified and ABT’s device growth remains above core medtech peers for two reporting periods.
• Exclude PRPO and NL from core books; use alerts for PRPO revenue conversion, cash-burn trajectory, and financing needs rather than treating stated operating leverage as investable until audited profitability and trading liquidity improve.